peoplePerson
Ryan B. Corcoran
Worked out why BRAF inhibitors fail in colorectal cancer and how to combine drugs to overcome it.
Physician-scientist whose laboratory defined EGFR-mediated feedback in BRAF-mutant colorectal cancer, leading to the BRAF-EGFR combinations now approved, and who uses ctDNA to track clonal resistance.
Role
Director, Gastrointestinal Cancer Center; Scientific Director, Termeer Center for Targeted Therapy
Institution
Specialisms
Colorectal cancerBRAF and KRAS resistanceLiquid biopsyTargeted therapy combinations
Profiles
| Title | Journal | Year |
|---|---|---|
| EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib | Cancer Discovery | 2012 |
Pages like this
not linked directly; found by shared links- PersonJosep Tabernero
Shares Encorafenib, Cetuximab, BRAF, EGFR.
- PersonDaniel A. Haber
Shares Massachusetts General Hospital Cancer Center, EGFR, Liquid biopsy (ctDNA).
- TrialBREAKWATER
Shares Encorafenib, Cetuximab, BRAF, EGFR.
- PersonRené Bernards
Shares Encorafenib, BRAF, EGFR, Colorectal cancer.
- PersonElena Élez
Shares Encorafenib, BRAF, KRAS, Colorectal cancer.
- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, BRAF, Colorectal cancer.
- TrialCRYSTAL & FIRE-3
Shares Cetuximab, KRAS, EGFR, Colorectal cancer.
- IdeaLook for the resistant sub-population before the first dose
Shares KRAS, EGFR, Liquid biopsy (ctDNA), Colorectal cancer.